Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:KZIA

Novogen Q2 2026 Earnings Report

Novogen logo
$14.24 -0.04 (-0.25%)
As of 12:09 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Novogen EPS Results

Actual EPS
-$1.34
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novogen Announcement Details

Quarter
Q2 2026
Date
3/19/2026
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Novogen Earnings Headlines

Novogen (NASDAQ:KZIA) Trading 3.7% Higher - Here's Why
June 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30827728
Kazia Therapeutics Appoints James Levine as Chief Financial Officer
June 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-james-levine-as-chief-financial-officer-302787604.html
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. Elon believes what Michael Robinson calls 'Project Unlimited' could unlock $100 trillion in potential growth. One little-known company sits at the center of it all, and most investors have no idea it exists. Position yourself before this company potentially hits the front page.tc pixel
June 15 at 1:00 AM  |  Weiss Ratings (Ad)
Kazia Therapeutics Expands Ongoing Phase 1b Trial of Paxalisib in Advanced Breast Cancer
May 26, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-ongoing-phase-1b-trial-of-paxalisib-in-advanced-breast-cancer-302781345.html
Kazia Therapeutics: Diverse Cancer Pipeline Still Needs A Major Catalyst
April 30, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4895704-kazia-therapeutics-diverse-cancer-pipeline-still-needs-a-major-catalyst
Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
April 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-strengthens-scientific-leadership-with-appointment-of-dr-sudha-rao-as-chief-scientific-officer-to-lead-next-generation-oncology-platform-302742491.html
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA) (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research.

Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.

View Novogen Profile
Earnings Tools